Publications by authors named "Geoffrey I Hackett"
Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study.
World J Mens Health
August 2024
Article Synopsis
- TRAVERSE was a large clinical trial examining the effects of testosterone therapy on men aged 45-80 with hypogonadism and cardiovascular disease risk, involving 5,246 participants.
- Participants were randomly assigned to receive either a testosterone gel or a placebo for an average of 27.1 months, while monitoring their cardiovascular health.
- The study concluded that testosterone therapy did not increase the risk of major adverse cardiovascular events or prostate-related issues, alleviating concerns previously raised by the FDA.
Background: Testosterone replacement therapy (TRT) improves health in some but not all men with type 2 diabetes (T2DM) and adult-onset testosterone deficiency (TD). Such heterogeneity is compatible with the concept of patient subgroups that respond differently to therapy.
Objectives: Use baseline SHBG and age to identify putative subgroups that demonstrate different responses in variables such as waist circumference and HbA1c following TRT.
Introduction: The age-related fall in male testosterone levels can have clinical consequences. The concentration of serum-free testosterone, the putative bioactive moiety, is mediated by carrier proteins, especially SHBG.
Aim: The aim of this study was to consider the nature of hormone binding to carriers with new insights into determining calculated free testosterone levels and review how SHBG and testosterone influence age-related mortality.
Introduction: Clinical guidelines indicate that hematocrit should be monitored during testosterone replacement therapy (TTh), with action taken if a level of 0.54 is exceeded.
Aim: To consider the extent of changes in hematocrit and putative effects on viscosity, blood flow, and mortality rates after TTh.
To address widespread concerns regarding the medical condition of testosterone (T) deficiency (TD) (male hypogonadism) and its treatment with T therapy, an international expert consensus conference was convened in Prague, Czech Republic, on October 1, 2015. Experts included a broad range of medical specialties including urology, endocrinology, diabetology, internal medicine, and basic science research. A representative from the European Medicines Agency participated in a nonvoting capacity.
View Article and Find Full Text PDFArticle Synopsis
- The paper examines the connection between late onset hypogonadism (LOH) and common health issues, particularly metabolic diseases, while evaluating the pros and cons of testosterone replacement therapy (TRT).
- Findings indicate that LOH is linked to poorer metabolic health and increased risk of cardiovascular problems, with a complicated relationship between hypogonadism, obesity, and insulin resistance.
- The authors suggest that TRT may improve body composition and metabolic health in those with LOH, but caution that more long-term research is needed to fully understand the relationship between low testosterone and aging-related health issues.
Introduction: Although sildenafil citrate (sildenafil) and tadalafil are efficacious and well-tolerated treatments for erectile dysfunction (ED), preference studies have shown that patients may favor one medication over the other.
Aim: To determine whether psychosocial outcomes differed when men with ED received tadalafil compared with sildenafil.
Main Outcome Measures: Measures included a treatment preference question, Psychological and Interpersonal Relationship Scales (PAIRS), and Drug Attribute Questionnaire.